

SCD 2020 Meeting—VIRTUALLY

August 10-12, 2020 -Day 1

9:00-5:00 pm	Monday's MEETING TIME
9:00-9:05 am	Welcome & Housekeeping W. Keith Hoots, MD , Director, Division of Blood Diseases & Resources; National Heart, Lung & Blood Institute
9:05-1:00 pm	SYMPOSIUM 1
9:05-12:00 pm	<i>Curative Therapies in Sickle Cell Disease</i> Lakshmanan Krishnamurti, MD , Section Director of BMT, Chair of Blood and Marrow Transplant, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta/Emory University
11:00-11:10 am	BREAK
12:00-1:30 pm	BMT for Adults With Sickle Cell Disease: STRIDE Pilot Study Shannon Smith , Emory University (by Invitation Only)
1:00-5:00 pm	SYMPOSIUM 2
1:00-2:00 pm	<i>Session Name: The Role of Cannabinoids in Sickle Cell Disease</i> Session Chairs: Kalpna Gupta, PhD and Susanna Curtis, MD <i>Medical Marijuana Certification for Adults With Sickle Cell Disease: Observations and Future Directions</i> Susanna Curtis, MD , Department of Medical Oncology/Hematology, Yale School of Medicine, New Haven, CT <i>Lessons from the Outcomes of Vaporized Cannabis Trial for Pain in SCD</i> Kalpna Gupta, PhD , University of California, Irvine, CA <i>Enhancing Endogenous Cannabinoids to Mitigate Sickle Pathobiology</i> Donovan Argueta, PhD , University of California Presidential Fellow, Department of Medicine, University of California, Irvine, CA
2:00-3:30 pm	<i>DBDR-CURE SCD-NIH-GATES Consortium</i> W. Keith Hoots, MD , Director, Division of Blood Diseases & Resources- DBDR Traci Mondoro, PhD , Branch Chief, Division of Blood Diseases & Resources <i>TopMed Update</i> Pankaj Qasba, PhD Program Officer, Division of Blood Diseases & Resources
3:30-5:00 pm	<i>SCDIC Session- Sharon Smith, PhD</i> , Division of Blood Diseases & Resources
3:30-3:45 pm	<i>Overview of the Sickle Cell Disease Implementation Consortium-SCDIC and a Protocol to Improve ED Care using Individualized Pain Plans</i> Paula Tanabe, PhD, RN , Duke University
3:45-3:55 pm	<i>Early Findings from the Integration of mHealth into the Care of Patients with Sickle Cell Disease to Increase Hydroxyurea Utilization (mESH Study)</i> Jane Hankins, MD , St. Jude Research Hospital
3:55-4:05 pm	<i>Moving the Needle in Sickle Cell Care: Expert Consensus on What Determines an Unaffiliated Patient;</i> Andrea Lamont, PhD , Wandersman Center
4:05-4:20 pm	Question & Answer Session
4:20-4:30 pm	Quality of Care Among Adolescents and Adults with SCD in the US: Analysis from the SCDC Julie Kanter, MD , University of Alabama
4:30-4:40 pm	<i>Patient Reported Outcomes in the Sickle Cell Disease Implementation Consortium Registry</i> Marsha Treadwell, PhD , UCSF Benioff Children's Hospital Oakland
4:40-4:50 pm	Hydroxyurea is Associated with Miscarriage and Stillbirth
4:50-5:00 pm	Victor Gordeuk, MD , University of Illinois at Chicago Question & Answer Session
	ADJOURN

SCD 2020 Meeting—VIRTUALLY

August 10-12, 2020 -Day 2

9:00-5:00 pm

Tuesday's Meeting Time

9:00-1:00 pm

SYMPOSIUM 3

9:00-9:10 am

Welcome & Housekeeping

Kim Smith-Whitley, MD; Comprehensive Sickle Cell Center for Women & Girls with Blood Disorders-FWGBD

9:10-9:45 am

Fertility and Fertility Preservation for Women With SCD

Lydia Pecker, MD, Director, Young Adult Clinic, Johns Hopkins Sickle Cell Ctr.,

9:45-10:40 am

Contraception

Naomi Tepper, MD, MPH, FACOG; Obstetrician/Gynecologist-CDC

Sarah O'Brien, MD, Pediatric Hematologist, Nationwide Children's Hospital

10:40-11:00 am

Summary Unified - Interactive/Integrated

Kim Smith-Whitley, MD; Director, Comprehensive Sickle Cell Center for Women & Girls with Blood Disorders-FWGBD

11:00-11:10 am

BREAK

11:10-12:10 pm

SCD-CARRE

Mark T. Gladwin, MD; Jack D. Myers Distinguished Professor & Chair

Chairman of the Department of Medicine; UPMC and the University of Pittsburgh School of Medicine

Darrell J. Triulzi, MD; Director, Division of Transfusion Medicine Dep. of Pathology University of Pittsburgh; Medical Director, Clinical Service Vitalant, Northeast Division

12:10-1:00 pm

Heymolysis & Immune Complications in SCD

Karina Yazdanbakhsh, PhD; Head of Laboratory, Member, New York Blood Center

1:00-1:10 pm

BREAK

1:10-5:00 pm

SYMPOSIUM 4

1:10-2:10 pm

Reviewing the Results

DISPLACE- Dissemination and Implementation of Stroke Prevention Looking at the Care Environment

Julie Kanter, MD, University of Alabama at Birmingham School of Medicine

2:10-5:00 pm

SCAPN- Sickle Cell Adult Provider Network

Dr. Kevin Kuo; MD, MSc, FRCPC

Clinician-Investigator and Staff Hematologist, Red Blood Cell Disorders Program, Therapeutic Apheresis Program, Division of Medical Oncology and Hematology, Department of Medicine, University Health Network

Assistant Professor, Division of Hematology, Department of Medicine, University of Toronto

Joy Ogunsile, MD

Assistant Professor, Division of Hematology & Oncology, Department of Medicine, UAB, Birmingham, AL

MEETING ADJOURN

SCD 2020 Meeting—VIRTUALLY

August 10-12, 2020 -Day 3

9:00-4:00 pm

Wednesday's Meeting Time

9:00-9:05 am

WELCOME & HOUSEKEEPING

Wally R. Smith, MD, *Florence Neal Cooper Smith Professor of Sickle Cell Disease, Vice Chair for Research, Division of General Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA*

9:00-12:00 pm

SYMPOSIUM 5

9:05-9:35 am

Essential Features of Sickle Cell Centers: Summary of the Evidence & a Consensus

Julie Kanter, MD, Director, Adult Sickle Cell Clinic; University of Alabama Birmingham; First Author, Blood Advances ADV-2020-001743R1 -- Accepted for Publication; Q&A 10 mins

9:35-10:30 am

Essential Features of Sickle Cell Centers: Summary of the Evidence & a Consensus

Modupe Idowu, MD Comprehensive Sickle Cell Center, University of Texas, Houston

Farzana Sayani, MC MSc; Director; Penn Comprehensive Sickle Cell Program, University of Pennsylvania

Hannah Lichtsinn, MD; Assistant Professor of Medicine and Pediatrics, HealthPartners, University of Minnesota

10:30-10:45 am

BREAK

10:45-11:45 am

Getting Administrative Buy-In & Writing a Business Plan

Patricia Engblom, MHA, FACHE, The Johns Hopkins Hospital

Janis Bozzo, MSN, RN, Yale New Haven Health

11:45-12:45 pm

COVID-19 Telemedicine & Re-Imaging the Adult Care Model (TBD)

Julie Kanter, MD

Wally R. Smith, MD VCU

Ify Osunkwo, MD, Director, Sickle Cell Disease Enterprise and Professor of Medicine Levine Cancer Institute Atrium Health, Charlotte, NC

Sophie Lanzkron MD, MHS, Professor of Medicine and Oncology Johns Hopkins School of Medicine; Baltimore, MD

12:45-1:00 pm

BREAK

1:00-3:30 pm

SYMPOSIUM 6

1:00-1:20 pm

ASH Sickle Cell Initiative

Charles S. Abrams, MD; Professor, Director; Penn-CHOP Blood Center for Patient Care & Discovery, University of Pennsylvania School of Medicine

1:20-1:40 pm

Quantification of Cerebral Metabolic Rate of Oxygen (CMRO2) in SCD

Wenbo Li, MD, Assistant Professor, Johns Hopkins School of Medicine

SCD 2020 Meeting—VIRTUALLY

August 10-12, 2020 -Day 3 cont.

1:40-2:00 pm

Wednesday Continued

2:00-2:20 pm

Protection Against Vaso-Occlusion With Daily Dosing of HBI-002, a Low Dose Oral Carbon Monoxide Formulation, In Sickle Cell Disease Mouse Models.

Authors/co-Authors: Edward Gomperts, MD, Howard Levy, MD, Mark Young, PhD: Hillhurst Biopharmaceuticals, Inc.

Fuad Abdulla, MSc; Chunsheng Chen, PhD; Greg Vercellotti, MD; John Belcher, PhD: Division of Hematology, Oncology and Transplantation University of Minnesota Department of Medicine, Vascular Research Center

2:20-2:30 pm

The Many Facets of KYC for Improving Vascular Function in SCD

Kirkwood A. Pritchard, Jr., PhD, Professor, Medical College of Wisconsin

2:30-4:00 pm

Session

2:30-2:45 pm

Ketamine and Novel Approached to Pain Management in the Sickle Cell Patient With Acute Pain

Steve Long, MD

2:45-3:00 pm

Ketamine and Novel Approached to Pain Management in the Sickle Cell Patient With Acute Pain

Steve Long, MD

3:00-3:15 pm

Intensive Training Program for Multidisciplinary Health Providers in Adult Sickle Cell Disease

Ward Hagar, MD

3:15-3:30 pm

Novel Laboratory Techniques To Determine Red Cell Health And Complication Risk In Patients Receiving Experimental Therapy

Frans Kuypers, PhD

3:30-3:45 pm

Iron Dysregulation in Sickle Cell Disease and its Clinical Effects and Management

Ash Lal, MD

3:45-4:00 pm

(Q& A)

Thank you for participating

CONFERENCE ADJOURNMENT

